VUB spin-off Confo Therapeutics announced that it has been awarded a €1 million grant from VLAIO. The grant will support the pre-clinical development of CFTX-1554, Confo’s lead candidate for neuropathic pain, which was initially discovered under a previous VLAIO research grant.
Confo is developing CFTX-1554 based on its promise as a potential treatment for patients living with peripheral neuropathic pain, a debilitating condition for which current treatment methods are ineffective or often result in severe side-effects or even addiction. The grant covers clinical trial application (CTA)-enabling studies to further characterize the pharmacology and safety of CFTX-1554 and the development of appropriate manufacturing protocols, as well as translational biomarker studies to examine the mechanism of action of AT2R modulation.